vs
STANDARD BIOTOOLS INC.（LAB）与null（TZOO）财务数据对比。点击上方公司名可切换其他公司
null的季度营收约是STANDARD BIOTOOLS INC.的1.1倍（$22.5M vs $19.6M），null净利率更高（-0.1% vs -177.4%，领先177.3%），null同比增速更快（8.7% vs -11.5%），null自由现金流更多（$1.4M vs $-23.1M），过去两年null的营收复合增速更高（1.1% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Travelzoo是一家互联网旅游服务企业，整合全球超2000家旅行、娱乐及本地商户（包括餐饮、spa场馆等）的特惠信息，目前在北美、欧洲及亚太地区共拥有2800万会员，在全球设有25个办事处。
LAB vs TZOO — 直观对比
营收规模更大
TZOO
是对方的1.1倍
$19.6M
营收增速更快
TZOO
高出20.2%
-11.5%
净利率更高
TZOO
高出177.3%
-177.4%
自由现金流更多
TZOO
多$24.5M
$-23.1M
两年增速更快
TZOO
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $22.5M |
| 净利润 | $-34.7M | $-20.0K |
| 毛利率 | 48.5% | 81.2% |
| 营业利润率 | -168.5% | 2.5% |
| 净利率 | -177.4% | -0.1% |
| 营收同比 | -11.5% | 8.7% |
| 净利润同比 | -28.8% | -100.6% |
| 每股收益（稀释后） | $-0.09 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABTZOO
| Q4 25 | — | $22.5M | ||
| Q3 25 | $19.6M | $22.2M | ||
| Q2 25 | $21.8M | $23.9M | ||
| Q1 25 | $40.8M | $23.1M | ||
| Q4 24 | — | $20.7M | ||
| Q3 24 | $22.1M | $20.1M | ||
| Q2 24 | $22.5M | $21.1M | ||
| Q1 24 | $45.5M | $22.0M |
净利润LABTZOO
| Q4 25 | — | $-20.0K | ||
| Q3 25 | $-34.7M | $150.0K | ||
| Q2 25 | $-33.5M | $1.4M | ||
| Q1 25 | $-26.0M | $3.2M | ||
| Q4 24 | — | $3.2M | ||
| Q3 24 | $-26.9M | $3.2M | ||
| Q2 24 | $-45.7M | $2.9M | ||
| Q1 24 | $-32.2M | $4.2M |
毛利率LABTZOO
| Q4 25 | — | 81.2% | ||
| Q3 25 | 48.5% | 79.6% | ||
| Q2 25 | 48.8% | 78.4% | ||
| Q1 25 | 48.4% | 82.0% | ||
| Q4 24 | — | 86.6% | ||
| Q3 24 | 54.9% | 87.3% | ||
| Q2 24 | 46.1% | 88.1% | ||
| Q1 24 | 53.1% | 88.0% |
营业利润率LABTZOO
| Q4 25 | — | 2.5% | ||
| Q3 25 | -168.5% | 2.2% | ||
| Q2 25 | -118.1% | 8.6% | ||
| Q1 25 | -80.8% | 16.4% | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | -120.9% | 20.1% | ||
| Q2 24 | -134.5% | 19.0% | ||
| Q1 24 | -132.2% | 25.4% |
净利率LABTZOO
| Q4 25 | — | -0.1% | ||
| Q3 25 | -177.4% | 0.7% | ||
| Q2 25 | -153.7% | 5.9% | ||
| Q1 25 | -63.8% | 13.7% | ||
| Q4 24 | — | 15.6% | ||
| Q3 24 | -122.0% | 15.8% | ||
| Q2 24 | -203.3% | 13.8% | ||
| Q1 24 | -70.6% | 19.3% |
每股收益（稀释后）LABTZOO
| Q4 25 | — | $0.02 | ||
| Q3 25 | $-0.09 | $0.01 | ||
| Q2 25 | $-0.09 | $0.12 | ||
| Q1 25 | $-0.07 | $0.26 | ||
| Q4 24 | — | $0.26 | ||
| Q3 24 | $-0.07 | $0.26 | ||
| Q2 24 | $-0.12 | $0.23 | ||
| Q1 24 | $-0.27 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $10.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $-7.5M |
| 总资产 | $539.6M | $45.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABTZOO
| Q4 25 | — | $10.0M | ||
| Q3 25 | $129.4M | $8.5M | ||
| Q2 25 | $158.6M | $10.4M | ||
| Q1 25 | $150.9M | $11.5M | ||
| Q4 24 | — | $17.1M | ||
| Q3 24 | $210.6M | $11.4M | ||
| Q2 24 | $269.8M | $12.6M | ||
| Q1 24 | $287.1M | $16.2M |
总债务LABTZOO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABTZOO
| Q4 25 | — | $-7.5M | ||
| Q3 25 | $399.7M | $-8.1M | ||
| Q2 25 | $424.5M | $-7.1M | ||
| Q1 25 | $454.6M | $-6.1M | ||
| Q4 24 | — | $-462.0K | ||
| Q3 24 | $489.3M | $-2.2M | ||
| Q2 24 | $510.3M | $966.0K | ||
| Q1 24 | $577.3M | $4.1M |
总资产LABTZOO
| Q4 25 | — | $45.2M | ||
| Q3 25 | $539.6M | $46.2M | ||
| Q2 25 | $557.0M | $46.7M | ||
| Q1 25 | $579.6M | $49.2M | ||
| Q4 24 | — | $54.7M | ||
| Q3 24 | $681.5M | $50.5M | ||
| Q2 24 | $708.7M | $51.5M | ||
| Q1 24 | $777.7M | $54.7M |
负债/权益比LABTZOO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $1.5M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $1.4M |
| 自由现金流率自由现金流/营收 | -118.1% | 6.4% |
| 资本支出强度资本支出/营收 | 4.5% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $5.6M |
8季度趋势，按日历期对齐
经营现金流LABTZOO
| Q4 25 | — | $1.5M | ||
| Q3 25 | $-22.2M | $-373.0K | ||
| Q2 25 | $-20.7M | $1.3M | ||
| Q1 25 | $-30.3M | $3.3M | ||
| Q4 24 | — | $7.8M | ||
| Q3 24 | $-27.9M | $5.3M | ||
| Q2 24 | $-39.0M | $3.3M | ||
| Q1 24 | $-62.5M | $4.6M |
自由现金流LABTZOO
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-23.1M | $-388.0K | ||
| Q2 25 | $-22.6M | $1.3M | ||
| Q1 25 | $-35.3M | $3.3M | ||
| Q4 24 | — | $7.8M | ||
| Q3 24 | $-30.1M | $5.3M | ||
| Q2 24 | $-41.0M | $3.3M | ||
| Q1 24 | $-63.3M | $4.6M |
自由现金流率LABTZOO
| Q4 25 | — | 6.4% | ||
| Q3 25 | -118.1% | -1.7% | ||
| Q2 25 | -103.6% | 5.4% | ||
| Q1 25 | -86.6% | 14.1% | ||
| Q4 24 | — | 37.7% | ||
| Q3 24 | -136.4% | 26.3% | ||
| Q2 24 | -182.2% | 15.4% | ||
| Q1 24 | -138.9% | 20.9% |
资本支出强度LABTZOO
| Q4 25 | — | 0.1% | ||
| Q3 25 | 4.5% | 0.1% | ||
| Q2 25 | 8.7% | 0.1% | ||
| Q1 25 | 12.4% | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | 10.2% | 0.2% | ||
| Q2 24 | 8.6% | 0.2% | ||
| Q1 24 | 1.7% | 0.2% |
现金转化率LABTZOO
| Q4 25 | — | — | ||
| Q3 25 | — | -2.49× | ||
| Q2 25 | — | 0.93× | ||
| Q1 25 | — | 1.04× | ||
| Q4 24 | — | 2.44× | ||
| Q3 24 | — | 1.67× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | — | 1.09× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
TZOO
暂无分部数据
